Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

996
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
996
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.5K
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.7K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.7K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

3.0K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
3.0K
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

6.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interleukin-6 is critical in the development of pulmonary vascular disease in <i>Gcn2-</i>deficient mice.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Targeting macrophage ferritin heavy chain mitigates ferroptosis and lung injury in experimental acute respiratory distress syndrome.

Nature communications·2026
Same author

DNA Methylation Variation in Blood Cells may Impact Platelet Function.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Longitudinal <sup>1</sup>H and <sup>129</sup>Xe Lung MRI in Patients With Post-COVID Residual Lung Abnormalities.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Proximity of city schools in Scotland to air quality monitors: an exploratory geomapping study in five Scottish cities.

BMJ public health·2026
Same author

Diffusing capacity of the lung for carbon monoxide, transfer coefficient of the lung for carbon monoxide and forced vital capacity/diffusing capacity of the lung for carbon monoxide in suspected systemic sclerosis-associated pulmonary hypertension: insights from the ASPIRE registry.

ERJ open research·2026

Related Experiment Video

Updated: Jan 1, 2026

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
06:35

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

1.1K

Hypoxia Modulates Platelet Purinergic Signalling Pathways.

Gordon G Paterson1,2, Jason M Young1,2, Joseph A Willson3

  • 1APEX (Altitude Physiology Expeditions), Edinburgh, United Kingdom.

Thrombosis and Haemostasis
|December 21, 2019
PubMed
Summary

Hypoxia increases platelet reactivity by altering adenosine diphosphate (ADP) pathways, specifically enhancing P2Y1 receptor activity and down-regulating P2Y12 signaling. This impacts individuals at high altitudes and those with sea-level hypoxia.

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.3K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

957

Related Experiment Videos

Last Updated: Jan 1, 2026

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
06:35

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

1.1K
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.3K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

957

Area of Science:

  • Cardiovascular Physiology
  • Hematology
  • Altitude Medicine

Background:

  • Hypoxia, whether from high altitude or sea-level conditions, is known to increase platelet reactivity.
  • Previous research suggests this effect is specific to adenosine diphosphate (ADP).
  • Understanding hypoxia's impact on ADP pathways is crucial due to the clinical significance of ADP-targeting drugs.

Purpose of the Study:

  • To investigate the effects of hypobaric hypoxia on platelet reactivity, particularly concerning adenosine diphosphate (ADP) pathways.
  • To assess changes in platelet aggregation and the function of ADP receptors (P2Y1 and P2Y12) under hypoxic conditions.

Main Methods:

  • Optimul aggregometry was used to assess platelet reactivity in lowland residents ascending to 4,700 m.
  • Platelet aggregation was measured in response to various agonists, including ADP, with and without P2Y1 and P2Y12 receptor inhibitors (MRS2500 and cangrelor).
  • Phosphorylation of vasodilator-stimulated phosphoprotein (VASP) was analyzed using the VASPFix assay to evaluate platelet activation status.

Main Results:

  • Hypobaric hypoxia reduced the efficacy of cangrelor in inhibiting ADP-induced platelet aggregation.
  • Basal VASP phosphorylation was increased under hypoxic conditions.
  • No increased platelet sensitivity to tested agonists was observed without inhibitors, with a notable decrease in sensitivity to thrombin receptor-activating peptide-6 amide.

Conclusions:

  • High altitude exposure leads to increased P2Y1 receptor activity.
  • Evidence suggests down-regulation of the P2Y12 pathway, indicated by increased VASP phosphorylation.
  • These alterations in ADP pathway activity have potential therapeutic implications for individuals experiencing hypoxia.